medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2018, Número 4

<< Anterior Siguiente >>

Rev Mex Urol 2018; 78 (4)


Tratamiento farmacológico de la hiperplasia prostática benigna. Revisión de la bibliografía

López-Ramos H, Medina-Rico M, Bastidas D, Lara B

Idioma: Español
Referencias bibliográficas: 49
Paginas: 321-334
Archivo PDF: 385.44 Kb.


RESUMEN

La hiperplasia prostática benigna afecta a 50% de la población mundial, principalmente a pacientes de 70-80 años de edad. Actualmente existen diferentes tratamientos, pero el farmacológico se considera el de primera línea. El objetivo de esta revisión fue encontrar la bibliografía relacionada con el tratamiento farmacológico de la hiperplasia prostática benigna. Para la investigación se revisaron las bases de datos y repositorios: Medline, Embase, Central, Scopus y LILACS. Solo se incluyeron estudios clínicos que evaluaron la eficacia de los diferentes fármacos indicados a pacientes con hiperplasia prostática benigna. Se registraron 1595 referencias revisadas por título y resumen, pero solo se seleccionaron 49 para la revisión de texto completo. Los medicamentos identificados fueron: tamsulosina, alfusosina, doxazosina, silodosina, dutasterida, finasterida, fesoterodina tadalafilo, sildenafilo y naftopidilo. Además, se encontraron estudios de fitoterapia que evaluaron la eficacia de Serenoa repens. La mayor parte de los medicamentos son efectivos para el tratamiento de los síntomas urinarios provocados por la hiperplasia prostática benigna. Los resultados coinciden con las recomendaciones de las últimas guías de práctica clínica. La elección del medicamento de primera línea depende del médico tratante, quien debe considerar, principalmente, los posibles eventos adversos y las preferencias del paciente.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. McVary KT, et al. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia 2010. [en línea]. Dirección URL: http://www.auanet.org/ benign-prostatic-hyperplasia-(2010-reviewed-and-validityconfirmed- 2014).

  2. Barry MJ, et al. The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. DOI: https://doi. org/10.1016/j.juro.2016.10.071

  3. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res 2008;20(Suppl 3):S11-8.

  4. Gallegos PJ, Frazee LA. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. DOI: https://doi.org/10.1592/phco.28.3.356

  5. Chung DE, Kaplan SA. Current role for combination therapy in male LUTS. Arch Esp Urol 2010;63(5):323-32.

  6. Novara G, et al. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data. DOI: https://doi.org/10.1111/bju.12906

  7. Seki N, et al. Non-inferiority of silodosin 4 mg once daily to twice daily for storage symptoms score evaluated by the International Prostate Symptom Score in Japanese patients with benign prostatic hyperplasia: a multicenter, randomized, parallel-group study. Int J Urol. DOI: https:// doi.org/10.1111/iju.12680

  8. Choo M, et al. Safety and efficacy of 8-mg once-daily vs 4-mg twice-daily silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (SILVER Study): a 12-week, double-blind, randomized, parallel, multicenter study. DOI: https://doi.org/10.1016/j. urology.2013.11.013

  9. Shirakawa T, et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter studyDOI: https://doi.org/10.1111/iju.12055

  10. Yamaguchi K, et al. Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. DOI: https://doi.org/10.1111/iju.12160

  11. Pande S, et al. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized controlled trial. Indian J Pharmacol 2014;46(6):601-7.

  12. Keten T, et al. Determination of the efficiency of 8 mg doxazosin XL treatment in patients with an inadequate response to 4 mg doxazosin XL treatment for benign prostatic hyperplasia. DOI

  13. Manjunatha R, et al. A randomized, comparative, openlabel study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol. 2016;48(2):134-40.

  14. Kumar S, Kondareddy C, Ganesamoni R, Nanjappa B, Singh S. Randomized controlled trial to assess the efficacy of the combination therapy of alfuzosin and tadalafil in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. DOI: https://doi.org/10.1111/luts.12016

  15. Masumori N, et al. a-1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study. DOI: https://doi.org/10.1111/j.1442-2042.2012.03165.x

  16. Kim JJ, et al. Efficacy and tolerability of tamsulosin 0.4 mg in Asian patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia refractory to tamsulosin 0.2 mg: a randomized placebo controlled trial. DOI: https://doi.org/10.1111/iju.12412

  17. Takeshita H, et al. Randomized crossover comparison of the short-term efficacy and safety of single half-dose silodosin and tamsulosin hydrochoride in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. DOI: https://doi.org/10.1111/luts.12106

  18. Karami H, et al. Comparing monotherapy with tadalafil or tamsulosin and their combination therapy in men with benign prostatic hyperplasia: a randomized clinical trial. Urol J 2016;13(6):2920-6.

  19. Oelke M, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. DOI: https://doi.org/10.1016/j.eururo.2012.01.013

  20. Perumal C, et al. A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement. Urol Ann 2015;7(1):74-78.

  21. Gacci M, et al. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsu losin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. DOI: https://doi.org/10.1111/j.1743- 6109.2012.02718.x

  22. Dmochowski R, et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J DOI: https://doi. org/10.1016/j.juro.2012.11.025

  23. Brock G, et al. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction. DOI: https://doi.org/10.1111/bju.12251

  24. Takeda M, et al. Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, doubleblind, placebo-controlled trial carried out in Japan and Korea. https://doi.org/10.1111/iju.12410

  25. Takeda M, et al. Tadalafil for the Treatment of Lower Urinary Tract Symptoms in Japanese Men with Benign Prostatic Hyperplasia: Results from a 12-week Placebo-controlled Dose-finding Study with a 42-week Open-label Extension. https://doi.org/10.1111/j.1757-5672.2012.00144.x

  26. Yokoyama O, et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. https://doi.org/10.1111/j.1442- 2042.2012.03130.x

  27. Singh DV, et al. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. DOI: https://doi.org/10.1111/ jsm.12357

  28. Regadas RP, et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial. Int Urol Nephrol 2013;45(1):39-43.

  29. Casabe A, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. DOI: https://doi.org/10.1016/j.juro.2013.09.059

  30. Fawzi A, et al. Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: A randomised, double-blind, placebo-controlled trial. DOI: https://doi.org/10.1016/j.aju.2016.11.001

  31. Joo KJ, et al. Comparison of [alpha]-blocker monotherapy and [alpha]-blocker plus 5[alpha]-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia. DOI: https:// doi.org/10.1177/147323001204000308

  32. Roehrborn C, et al. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. DOI: https://doi.org/10.1111/bju.12500

  33. Odusanya BO, et al. Short-term Effect of Tamsulosin and Finasteride Monotherapy and their Combination on Nigerian Men with Benign Prostatic Hyperplasia. Niger J Surg 2017;23(1):5-10.

  34. Konstantinidis C, et al. Lower urinary tract symptoms associated with benign prostatic hyperplasia: combined treatment with fesoterodine fumarate extended-release and tamsulosin-- a prospective study. https://doi.org/10.1159/000345050

  35. Cai J-L, et al. Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chin Med J 2016;129(24):2899-2906.

  36. Ryu Y, et al. Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. DOI: https://doi.org/10.1159/000366521

  37. Argirovic A, Argirovic D. Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia? Vojnosanit Pregl 2013;70(12):1091-6.

  38. Morgia G, et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). DOI: https://doi. org/10.1002/pros.22866

  39. Song CS, et al. Effect of Longbishu capsule () plus doxazosin on benign prostatic hyperplasia: a randomized controlled trial. Chin J Integr Med 2014;20(11):818-22.

  40. Barrera M. Diferencias estadísticamente significativas vs. relevancia clínica. Rev CES Med 2008;22(1):89-96.

  41. Abrams P, et al. Evaluation and Treatment of Lower Urinary Tract Symptoms in Older Men. DOI: DOI: https://doi. org/10.1016/j.juro.2012.11.021

  42. Barragán-Arteaga I, Reyes-Vallejo L. Combination therapy for the treatment of lower urinary tract symptoms in men. Rev Mex Urol 2016;76(6):360-9.

  43. NICE Clinical Guidelines. National Clinical Guideline Centre. The Management of Lower Urinary Tract Symptoms in Men. London: Royal College of Physicians (UK); 2015. [en línea]. Dirección URL: https://www.ncbi.nlm.nih.gov/books/ NBK65073/.

  44. Yeo JK, et al. Korean clinical practice guideline for benign prostatic hyperpla. DOI: https://doi.org/10.4111/icu.2016.57.1.30

  45. Singapore Urological Association Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Guidelines Committee 2015. Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia. Singapore Med J. doi: 10.11622/smedj.2017082

  46. Nunes RV, et al. Treatment of benign prostatic hyperplasia. Rev Assoc Med Bras. DOI: http://dx.doi.org/10.1590/1806- 9282.63.02.95

  47. López-Ramos H, et al. Guía de manejo de la hiperplasia prostática benigna. Sociedad Colombiana de Urología 2014. DOI: 10.1016/j.uroco.2015.04.005

  48. Consejo de Salubridad General. Guía de Práctica Clínica. Diagnóstico y tratamiento de la hiperplasia prostática benigna [en línea]. Dirección URL: http://www.cenetec.salud.gob. mx/descargas/gpc/CatalogoMaestro/176_GPC_HIPERPLASIA_ PROSTATICA/Gpc_hipertrofia_prostatica.pdf. [Consulta: 5 de julio 2108].

  49. Dahm P, et al. Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review and meta-analysis. DOI: https://doi.org/10.1016/j.eururo.2016.09.032




2020     |     www.medigraphic.com